Baker Bros. Advisors TSHA Position
Active7-Fund ConvergenceBaker Bros. Advisors held their position in Taysha Gene Therapies, Inc. (TSHA) in Q4 2025, holding $22.0M worth of shares across 4,004,756 shares.
The position was first reported in Q3 2023 and has been tracked across 10 quarterly 13F filings.
TSHA is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for TSHA-101 in 332 days (Mar 12, 2027), making the timing of Baker Bros.'s position particularly relevant.
Short interest stands at 18.1% of float with 17.8 days to cover, indicating significant bearish positioning against Baker Bros.'s long thesis.
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Full company profile →Short Interest
18.1%
17.8 days to cover
Baker Bros. Advisors TSHA Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Held | 4,004,756 | — | $22.0M |
| Q3 2025 | Held | 4,004,756 | — | $13.1M |
| Q2 2025 | Held | 4,004,756 | — | $9.3M |
| Q1 2025 | Held | 4,004,756 | — | $5.6M |
| Q4 2024 | Held | 4,004,756 | — | $6.9M |
| Q3 2024 | Held | 4,004,756 | — | $8.1M |
| Q2 2024 | Held | 4,004,756 | — | $9.0M |
| Q1 2024 | Held | 4,004,756 | — | $11.5M |
| Q4 2023 | Increased | 4,004,756 | +1,500,000 | $7.1M |
| Q3 2023 | New | 2,504,756 | +2,504,756 | $7.9M |
Frequently Asked Questions
Does Baker Bros. Advisors own TSHA?
Yes. As of Q4 2025, Baker Bros. Advisors holds 4,004,756 shares of Taysha Gene Therapies, Inc. (TSHA) valued at $22.0M. This data comes from their SEC 13F filing.
How many hedge funds own TSHA?
7 specialist biotech hedge funds currently hold TSHA, including RA Capital Management, Avoro Capital Advisors, RTW Investments and 3 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Baker Bros. Advisors first buy TSHA?
Baker Bros. Advisors's position in TSHA was first reported in Q3 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Baker Bros. Advisors's TSHA position increasing or decreasing?
Baker Bros. Advisors held their TSHA position unchanged in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TSHACompany Page →
All fund holders, insider trades, catalysts, and cash runway
Baker Bros. AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →